Eleni Stamellou, Turgay Saritas, Marc Froissart, Florian Kronenberg, Peter Stenvinkel, David C Wheeler, Kai-Uwe Eckardt, Jürgen Floege, James Fotheringham
BACKGROUND: The consequences of chronic kidney disease (CKD) can be addressed with a range of pharmacotherapies primarily prescribed by nephrologists. More accurate information regarding future CKD-related pharmacotherapy requirements could guide clinical decisions including follow-up frequency. METHODS: Following assignment to derivation and validation groups (2,1), variables predicting individually future use of vitamin D receptor agonists (VDRA), phosphate binders, erythropoiesis stimulating agents (ESAs) and iron were identified using logistic regression in a prospective cohort study containing demography, comorbidity, hospitalization, laboratory, and mortality data in patients with CKD stage G4/G5 across six European countries...
February 20, 2024: BMC Nephrology